weight loss drug news today glp-1 october 2025 Rhode Island considers ending Medicaid coverage of drugs for • Rhode Island Current Beyond GLP-1: the next wave
Description
Drug Type/Class 18.8.3
Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
Advanced GLP-1 Weight Loss Advanced GLP-1s combine dual-agonist action to improve weight loss outcomes by enhancing insulin sensitivity and reducing hunger, integrated into a customized care plan
Understanding those differences is key to choosing what actually fits your body, lifestyle, and long-term goals
[DOI] [PubMed] [Google Scholar] 83.Bendotti G., Montefusco L., Lunati M.E., Usuelli V., Pastore I., Lazzaroni E., et al
Financial Health & Key Metrics Lillys recent results reflect both growth and margin expansion
